References

  1. Chu KKW, Ho SS, Chow AHL. Coriolus versicolor a medicinal mushroom with promising immunotherapeutic values. J Clin Pharmacol 2002; 42: 976-84.
  2. Miyazaki T, Yadome T, Siguira M, Ito, and Fujii K. Chemical structure of anti-tumour polysaccharide, coriolan, produced by Coriolus versicolor. Chemical and Pharmaceutical Bulletin. 1974; 22: 1739-1742.
  3. Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporoceae. Gen Pharmacol. 1998; 30: 1-4.
  4. Yang QY, Jong SC, Li XY, Zhou JX, Chen RT, Xu LZ. Antitumour and immunomudulating activities of the polysaccharide –peptide (PSP) of Coriolus versicolor. J Immunol Immunopharmacol. 1992; 12: 29-34.
  5. Fisher M, Li Xi-yang. Anti-cancer effects and mechanisms of polysaccharide-K (PSK): Implications of cancer immunotherapy. Anticancer Res. 2002; 22: 1737-1754.
  6. Ueno S, Yoshikumi, Hirose F, Omura Y et al. Method of producing nitrogen-containing polysaccharides. US Patent No. 4202969, 1980.
  7. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK). Cancer Treatment Reviews. 1984; 11:131-155.
  8. Czop JK. The role of beta glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. Pathol. Immunopathol. Res. 1986; 5: 286-296.
  9. Di Renzo L, Yefendof E, Klein E. The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18). Eur J Immunol 1991; 21: 1755-1758.
  10. Ohmori K, Oka T. Effects of OK-432 or PSK on in vitro activation of T lymphocytes from human peripheral blood. Biotherapy. 1990; 4: 712-716.
  11. Ishihara Y, Iijima H, Matsunaga K. Contribution of cytokines on the suppression of lung metastasis. Biotherapy. 1998; 11: 267-75.
  12. Ishihara Y, Fujii T, Iijima H, Saito K, Matsunaga K. The role of neutrophils as a cytotoxic cells in the lung metastasis: suppression of tumour cell metastasis by a biological response modifier. In Vivo. 1998; 12: 175-82.
  13. Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M et al. PSK, a protein-bound polysaccharide overcomes defective maturation of dendritic cells exposed to tumour-derived factors in vitro. Int, J Oncology, 2002; 20: 1189-1195.
  14. Kariya Y, Inoue N, Kihara T, Okamoto N, Sugie K et al. Activation of human natural killer cells by the protein-bound PSK independently of interferon and interleukin 2. Immunol Letters. 1992; 31: 241-246.
  15. Kanazawa M, Mori Y, Ypshihara K, Iwadate M, Suzuki S et al. Effect of PSK on the maturation of dendritic cells derived from human peripheral blood monocytes. Immunol Lett. 2004 15: 229-38.
  16. Kikichi Y, Kizawa I, Oomori K, Iwano I, Kita T et al. Effects of Cimetidine and PSK on interleukin 2 production by PBL in patients with advance ovarian carcinoma during the course of chemotherapy. Acta Obst Gynaecologica Japonica. 1987; 39: 1987-1992.
  17. Hiramatsu S. Immunohistochemical study of spleens in gastric cancer. J Jap Surgical Soc. 1987; 88: 1591-1603.
  18. 18. Tsuru S, Nomoto K, Taniguchi M, Kitani H et al. Depression of macrophage functions and T cell mediated immunity to Listeria infection in tumour-bearing mice and its prevention by PSK. Cancer Immunol Immunother. 1984; 18. 160-163.
  19.  Kondo M. Torisu M. Evaluation of an anticancer activity of a protein-bound polysaccharide PSK(Krestin). Basic mechanism and clinical treatment. Academic Press, Inc., pp 623-636
  20. Yokoe Y. Kato H. Takemura S et al. Effect of long-term administration of OK-432 (picibanil), PSK (Krestin) and levamisole on immune responses in aged subjects without malignancy. Jap J Clin Oncol. 1979; 9(2): 209-214
  21. Okuzawa M. Shonohara H. Kobayashi T et al, PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumour-derived factors. Int.J Oncol. 2002; 20: 1189-1195
  22. Kanazawa M. Yoshihara K. Abe H et al. Effects of PSK on T dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res. 2005; 25:443-450.
  23. Kato M, Hirose K, Hakzaki M, Ohno M et al 1995. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 1995; 40: 152-156.
  24. Ozaki S, Okazaki T, Nakao K. Biological response modifiers (BRM) as antigens: III. T cell lines specific for BRM kill tumour cells in a BRM-specific manner. Cancer Immunol Immunother 1995; 40: 219-227.
  25. Tsuru S, Oguchi M, Mashiko M, Asio S, Zinnaka Y, Nomoto K. Effect of PSK on tumour-specific immunity induced by MMC-treated synergenic  tumourcells. Jap J Cancer and Chemotherapy. 1982; 9: 1634-1639.
  26. Kanoh T, Matsunaga K, Saito K, Fujii T. Suppression of in vivo tumour-induced angiogenesis by protein-bound polysaccharide. In Vivo. 1994; 8: 247-250.
  27. Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes : an overview. Cancer Epidemiol Biomarkers and Prevention. 1995; 4: 275-281.
  28. Zhang H, Morosaki T, Matsunaga H, Sato et al . Protein-bound polysaccharide PSK inhibits tumour invasiveness by down-regulation of TGF-beta1 and MMPs. Clin Exp Metastasis. 2000; 18: 343-352.
  29. Gotoh K, Gouchi A, Akura Y, Tanaka N, Orita K. Augmentation of cytotoxicity of tumour-infiltrating lymphocytes by biological response modifiers. Int J Immunopharmacol. 1991; 13: 485-492.
  30. Iguchi C, Nio Y, Takeda H, Yamasawa K et al. Plant polysaccharide PSK: cytostatic effects on growth and invasion; modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumour cell surface. Anticancer Res. 2001; 21: 1007-13.
  31. Kariya K, Nakamura K, Nomoto K, Matam S, Saigenji K. Mimicking of superoxide dismutase activity by protein-bound polysaccharide of Coriolus versicolor QUEL and oxidative stress relief for cancer patients. Molecular Biotherapy. 1992; 4: 40-46.
  32. Mau JL, Lin HC, Chen CC. Antioxidant properties of several medicinal mushrooms. J Agric Food Chem. 2002; 50: 6072-7.
  33. Kobayashi H, Matsunaga K, Masahhiko F. PSK as a chemoprotective agent. Cancer Epidemiology Biomarkers and Prevention. 1993; 2: 271-276.
  34. Matsui H, Setogawa T, Noara H, Tanaka O. The effects of PSK, a biological response modifier, on congenitalocular abnormalities induced by X-irradiation. Histol and Histopath. 1995; 10: 47-54.
  35. Nakajima T. Ichikawa S. Uchida S. Komada T. Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by 3’-methyl1-4-dimethylaminoazobenzene in rats. Clin Ther 1990; 12: 385-392
  36. Ooshiro M. Sugishita Yu-I, Tanaka H. et al. Regulation of perioperative immunological changes following laparotomy: effects of biological response modifier (BRM) on surgical stress. Immunol. Letters 2004; 93: 33-38
  37. Toge T, Kegoya Y, Yamaguchi Y, Baba N et al. Surgical stress and immunosuppression in cancer patients. Jap J Cancer and Chemother1989; 16: 1115-1121.
  38. Ogawa K, Hirai M, Katsube T, Kajiwara T. Surgical stress and lymphocyte function: effects of PSK to prevent cellular immunosuppression. J Nippon Medical School. 1993; 60: 316-320.
  39. Munro JA. The use of the medicinal mushroom Coriolus MRL as an immuno-therapeutic agent in the treatment of patients with chronic fatigue syndrome. J Integrative Med. 2004;8: 101-108
  40. Ando T, Motokawa I, Sakurai et al. Effects of PSK on resistance to bacterial infection in splenectomised mice. Oncology. 1998; 45:224-229
  41. Tsuru S. Depression of early protection against influenza virus infection by cyclophophamide and its restoration by protein-bound polysaccharide. Kitasato Archives of Exp Med 1992; 65: 97-110.
  42. Collins RA, TB Ng. Polysaccharopeptide from C versicolor has potential for use against human immunodeficiency virus type 1 infection. In: Yang QY (ed) InternationalSymposium on Traditional; Chinese Medicine and Cancer: Development and Clinical Validation-Advances Research in PSP 1999; pp 181-186, Hong Kong Association for Health Care Ltd.
  43. Monma Y, Kawana T, Shimizu F. In vitro inactivation of herpes simplex virus by a biological response modifier, PSK. Antiviral Res 1997; 35: 131-138.
  44. Liu A, Arbiser JL, Holmgren A, Klein G, E Klein. PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte product IL-15 and IL-12. Blood 2005; 105(4): 1606-1613.
  45. Sakurai K, Motokawa I, Ando T, Ohmura Y, Saito K et al. Effect of a biological response modifier, PSK, on intestinal flora of tumour bearing mice. In Vivo. 1993; 7: 175-179.
  46. Katano M, Yamamoto H, Torisu M. A suppressive effect of PSK, a protein-bound polysaccharide preparation, on tumour growth: a new effect of PSK on cell motility. Jap J Cancer and Chemother. 1987; 14: 2321-2336.
  47. Hsieh T, Wu J. Cell growth and gene modulatory activities of Yun zhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen- dependent and androgen-sensitive human prostrate cancer cells. In J Oncol. 2001.; 18: 81-88.
  48. Torisu M, Hayashi Y, Ishimitsu T, Fujimure T et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990; 31: 261-268.
  49. Wong CK, Tse PS, Wong EL, Leung PC, Fung KP, Lam CW. Immunomodulatory effects of Yun Zhi and Danshen capsules in healthy subjects- a randomised, double-blind, placebo-controlled crossover study. Int Immunopharmacol. 2004; 4: 201-11.
  50. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K et al. Randomized, controlled study on adjuvant immunotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum. 1992; 35: 123-130.
  51. Ohwada S, Kawate S, Ikeya T, Yokomori T, Kusaba T et al. Adjuvant therapy with protein-bound polysaccharide K and tegafur/uracil in patients with Stage II or III colorectal cancer: Randomized, controlled trial. Dis Colon Rectum. 2003; 46: 1060-1068.
  52. Ohwada S, Ikeya T, Yokomori T, Kusab T, Roppongi T, et al. Adjuvant immunotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004; 90: 1003-1010.
  53. Ito K, Nakazato H, Koike A et al, Long-term effect of 5-flurouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7 year follow-up. Int J Colorectal Dis. 2004; 19(2): 157-64
  54. Sukamoto J, Morita S, Oba K et al. Efficacy of adjuvant immunochemotherpay with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomised controlled clinical trials. Cancer Immunol Immunother. 2006; 55:404-411.
  55. Hayakawa H, Mitsuibashi N, Saito Y, Takahashi M et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small lung cancer. Anticancer Res. 1993; 13: 1815-1820.
  56. Toi M, Hattori, Akagi M et al. Randomised adjuvant trial to evaluate the addition of Tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemo endocrine Therapy for Breast Cancer Organisation. Cancer 1992; 70 (10): 2475-83.
  57. Iino Y, Yokoe T, Maemura M, Horiguchi J, Takel H et al. Immunochemotherapies versus Chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res. 1995; 15: 2907-2912.
  58. Yokoe T, Iimo Y, Takei H, Horiguchi J et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunotherapy with PSK. Anticancer Res. 1997; 17: 2815-2818.
  59. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J, Efficacy of immunotherapy as adjuvant treatment after curative resection of gastric cancer Lancet 1994; 343: 1122-26.
  60. Ogoshi K, Miyaji M, Nakmura K, Kondoh Y, Makuuchi H, Tajima T. Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute phase reactants. Cancer Immunol Immunother. 1998; 46: 14-20.
  61. Ogoshi K,Satou H, Isono K, Mitomi T Endoh M, Sugita M. Possible predictive markers of immunotherapy of oesophageal cancer retrospective analysis of a randomised study. The Co-operative Study Group for Oesophageal Cancer in Japan. Cancer Invest. 1995; 13: 363-369.
  62. Go P, Chung CH. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. J Int Med Res. 1989; 17: 141-149
  63. Ohno R, Yamada K, Masaoka T, Oshima T, Amaki I et al. 1984. A randomized trial of chemo immunotherapy of acute non-lymphocytic leukaemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother. 1984; 18: 149-154.
  64. Kawa K, Konishi S, Tsujino G, Mabuchi S. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy. Biomedicine and Pharmacotherapy. 1991; 45: 113-116.
  65. Pharmaceutical Affairs Bureau, Ministry of Health and Welfare. Collection of information on Drug Adverse Reaction No. 48, Tokyo Ministry of Health and Welfare, 1980.
  66. Ikuzawa M, Matsunaga K, Nishiyama S, Nakjima S, Kobayashi Y et al. Fate and distribution of an antitumour protein-bound polysaccharide PSK (Krestin). Int J Immunopharmacol. 1988; 10: 415-423.
  67. Fujita H, Ogawa K, Ikuzawa M, Muto S et al. Effects of  PSK ( Krestin) on drug-metabolizing enzymes with special reference to the activation of FT-207. Jap J Cancer and Immunother. 1986; 13: 2653-2657.
  68. Park KS, Park S, Jung JC, Ha HC et al. Production of protein-bound polysaccharides by solid fermentation of Coriolus versicolor Han’guk Kyunhakhoechi 1994; 20: 72-76.
  69. Chen Y, Chang P, Yang Y, Wang K. Preparation of polysaccharides from Polystictus versicolor by submerged culture. Chung Ts’ao Yao. 1981; 12:18-9.
  70. Zhou S, Feng P, Tang L. Rheological behaviour of mycelial suspensions of Polystictus versicolor during cultivation in an internal airlift-loop reactor by submerged culture. Huangou Xuebou. 1994; 45: 371-4 (in Chinese).
  71. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern. Med Rev 2000; 5: 4-27.
  72. American National Cancer Research Centre. Applied Microbiol. 1989; 34: 183-264.